• China's National Medical Products Administration accepted Simcere Pharmaceutical's zemprocitinib application for treatment of moderate-to-severe active rheumatoid arthritis.
• Jointly developed with Lynk Pharmaceuticals, zemprocitinib now has two indications under regulatory review in China, including adult moderate-to-severe atopic dermatitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261106-12403313), on November 06, 2026, and is solely responsible for the information contained therein.